We are live on
!
Find out more
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FVFIGP
1
Flagship Ventures Fund IV General Partner
Cambridge,
Massachusetts
| $87.2M | +$87.2M | +480,666 | New |
|
|
DM
2
Deerfield Management
New York
| $38M | +$38M | +209,522 | New |
|
3
Fidelity Investments
Boston,
Massachusetts
| $37.8M | +$54.9M | +302,729 | New |
|
|
AC
4
Aisling Capital
New York
| $16.5M | +$16.5M | +90,857 | New |
|
|
RG
5
Redmile Group
San Francisco,
California
| $15.1M | +$17.2M | +94,618 | New |
|
|
BBA
6
Baker Bros. Advisors
New York
| $3.71M | +$3.71M | +20,447 | New |
|
|
EAM
7
Eventide Asset Management
Boston,
Massachusetts
| $2.72M | +$2.72M | +15,000 | New |
|
|
FCMI
8
Foresite Capital Management III
Larkspur,
California
| $2.72M | +$2.72M | +15,000 | New |
|
9
Alyeska Investment Group
Chicago,
Illinois
| $1.27M | +$1.27M | +7,000 | New |
|
|
CC
10
Casdin Capital
New York
| $908K | +$908K | +5,000 | New |
|
|
WMSA
11
Weiss Multi-Strategy Advisers
New York
| $832K | +$832K | +4,586 | New |
|
12
Goldman Sachs
New York
| $363K | +$363K | +2,000 | New |
|